Patents by Inventor Catherine Anne Eberlein

Catherine Anne Eberlein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination of EGFR Inhibitor and MEK Inhibitor for use in the treatment of NRAS mutated cancer
    Publication number: 20210177844
    Abstract: The invention relates to the methods for identifying resistance to cancer therapy, by identification of an E63K NRAS mutation, a G12V NRAS mutation or a gain of copy number of NRAS gene. A further aspect of the invention relates to methods of treatment that may overcome such resistance mechanisms, involving the use of an EGFR inhibitor in combination with a MEK inhibitor for the treatment of cancers involving an NRAS mutation selected from E63K, G12V, G12R, G12A, G12D, G12S and G12C, and/or cancer involving a gain of copy number of NRAS gene.
    Type: Application
    Filed: December 16, 2020
    Publication date: June 17, 2021
    Inventors: Darren Anthony Edward Cross, Catherine Anne Eberlein
  • Combination of EGFR Inhibitor and MEK Inhibitor for use in the treatment of NRAS mutated cancer
    Publication number: 20200237758
    Abstract: The invention relates to the methods for identifying resistance to cancer therapy, by identification of an E63K NRAS mutation, a G12V NRAS mutation or a gain of copy number of NRAS gene. A further aspect of the invention relates to methods of treatment that may overcome such resistance mechanisms, involving the use of an EGFR inhibitor in combination with a MEK inhibitor for the treatment of cancers involving an NRAS mutation selected from E63K, G12V, G12R, G12A, G12D, G12S and G12C, and/or cancer involving a gain of copy number of NRAS gene.
    Type: Application
    Filed: April 2, 2015
    Publication date: July 30, 2020
    Applicant: AstraZeneca AB
    Inventors: Darren Anthony, Edward Cross, Catherine Anne Eberlein
  • TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
    Publication number: 20120114667
    Abstract: The invention relates to targeted binding agents against ?5?1 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to ?5?1. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of ?5?1 and as diagnostics.
    Type: Application
    Filed: December 21, 2009
    Publication date: May 10, 2012
    Applicant: MEDIMMUNE LIMITED
    Inventors: Catherine Anne Eberlein, Ian Foltz, Jaspal Singh Kang, Jane Kendrew, Avril Alfred, Simon Thomas Barry
  • TARGETED BINDING AGENTS DIRECTED TO a5ß1 AND USES THEREOF
    Publication number: 20120107324
    Abstract: The invention relates to targeted binding agents against ?5?1 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to ?5?1. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of ?5?1 and as diagnostics.
    Type: Application
    Filed: December 21, 2009
    Publication date: May 3, 2012
    Inventors: Catherine Anne Eberlein, Ian Foltz, Jaspal Singh Kang, Jane Kendrew, Avril Alfred, Simon Thomas Barry